Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 1997

View Archived Issues

Ethical Holdings: FY 1997 highlights

Andrx: Q3 and nine-month highlights

Enzo Biochem: Q4 1997 highlights

Biovail: Q3 and nine-month highlights

Transkaryotic Therapies: Q3 1997 highlights

CellPro: Q2 1997 highlights

InSite Vision: Q3 1997 highlights

First market introduction for dolasetron

Zeneca selects new HLE inhibitor for clinical development

Antihypertensive and antianginal efficacy of mibefradil confirmed in clinical trials

Intercardia to acquire Transcell

Phase I trials begin on TNT in glioma patients

FDA approves generic formulation of oxycodone/acetaminophen

Genetronics cleared to proceed with electroporation trial in France

Safety of nemorubicin (daily x 3 every 28 days) evaluated in phase I trial

Patient enrollment complete for phase II trial of memantine

Neuropeptide Y5 receptor emerges as an important new target in obesity

U.S. clinical stroke trial supports efficacy and safety of citicoline

Melatonin evaluated for bipolar disorder

Receptagen and Scitech Genetics approach merger

NIH scientists identify nicotinic receptor in hippocampus

NIAID awards Progenics funds for HIV program

Cellegy to acquire nitroglycerin-based product for anorectal conditions

Heat shock proteins: a new vaccine strategy

New proton pump inhibitors from Apotex

LG Chemical reports new compounds for AIDS

New neuroprotectants from HHS

U.S. patent issued for Cambridge NeuroScience's drug delivery system

TNF/PDE inhibitors disclosed by Rhone-Poulenc Rorer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...